A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: The TARGET study

• Main Authors: Tim R. Cressey, Oraphan Siriprakaisil, Virat Klinbuayaem, Justice Quame-Amaglo, Rachel W. Kubiak, Pra ornsuda Sukrakanchana, Kanchana Than-in-at, Jared Baeten, Wasna Sirirungsi, Ratchada Cressey, Paul K. Drain
• 格式: 雜誌
• 出版: 2018
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85023612304&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/47100

© 2017 The Author(s). Background: Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV, but existing tools to monitor drug adherence are often inaccurate. Detection of tenofovir (TFV) in accessible biological samples, such a...